From the Desk of Steve Strazza and Alfonso Depablos
The only insider buy on today’s list comes via a Form 4 filing by Entrada Therapeutics Inc $TRDA director Peter S. Kim.
Kim reported the acquisition of 25,000 shares, equivalent to $364,672, in the small-cap biotech company.